Furthermore, PPARα activation downregulates IL-1β and TNFα in the liver via inhibition of NF-κB and suppresses hepatosteatosis via upregulation of fatty acid oxidation gene expression in rodent NAFLD models (31, 32). This evidence concerns the gene IL1B and metabolic dysfunction-associated steatotic liver disease.